NCT03468374

Brief Summary

Role of SPECT/CT in detection of sentinel lymph node in patients with breast cancer that is in early stage with small mass with no nodal or distant metastasis using radioactive material nannocolloid that can change surgical approach

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
4

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jul 2018

Longer than P75 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 4, 2018

Completed
12 days until next milestone

First Posted

Study publicly available on registry

March 16, 2018

Completed
4 months until next milestone

Study Start

First participant enrolled

July 1, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2019

Completed
2.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2022

Completed
Last Updated

March 16, 2018

Status Verified

February 1, 2018

Enrollment Period

1.3 years

First QC Date

March 4, 2018

Last Update Submit

March 15, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Role of SPECT/CT in sentinel lymph node detection in breast cancer

    Early detection of sentinel lymph node in patients with breast cancer using SPECT/CT by radioactive material nanocolloid to change surgical approach

    3 years

Study Arms (2)

Lymphoscintigraphy

ACTIVE COMPARATOR

Nuclear Medicine diagnostic device using radioactive material

Device: lymphoscintigraphy

Single Photon Emission Tomography

ACTIVE COMPARATOR

Nuclear Medicine diagnostic device using fusion technique between SPECT and CT

Device: Single Photon Emission Tomography

Interventions

Nuclear Medicine diagnostic device using radioactive material

Lymphoscintigraphy

Nuclear Medicine diagnostic device using fusion technique between SPECT and CT

Single Photon Emission Tomography

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients 18≤ years' old, female gender.
  • Patients with histopathologically proven breast cancer.
  • Patients with early stage and invasive breast cancer stage T1 with mass no more than 2 cm in greatest dimension or stage T2 with mass more than 2 cm but no more than 5 cm in greatest dimension with no clinical evidence of axillary lymph node metastasis(N0) and no remote metastasis (M0).

You may not qualify if:

  • Patients with LABC, multifocal breast cancer or distant metastasis.
  • Clinical, histological or radiological evidence of regional nodal metastasis.
  • Prior major breast or axillary operations that could interfere with lymphatic drainage.
  • Pregnancy.
  • Inability to sign informed consent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (7)

  • Samphao S, Eremin JM, El-Sheemy M, Eremin O. Management of the axilla in women with breast cancer: current clinical practice and a new selective targeted approach. Ann Surg Oncol. 2008 May;15(5):1282-96. doi: 10.1245/s10434-008-9863-8. Epub 2008 Mar 11.

    PMID: 18330650BACKGROUND
  • Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994 Sep;220(3):391-8; discussion 398-401. doi: 10.1097/00000658-199409000-00015.

    PMID: 8092905BACKGROUND
  • Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006 Jan 1;106(1):4-16. doi: 10.1002/cncr.21568.

    PMID: 16329134BACKGROUND
  • Cheng G, Kurita S, Torigian DA, Alavi A. Current status of sentinel lymph-node biopsy in patients with breast cancer. Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):562-75. doi: 10.1007/s00259-010-1577-z. Epub 2010 Aug 11.

    PMID: 20700739BACKGROUND
  • Somasundaram SK, Chicken DW, Keshtgar MR. Detection of the sentinel lymph node in breast cancer. Br Med Bull. 2007;84:117-31. doi: 10.1093/bmb/ldm032. Epub 2008 Jan 3.

    PMID: 18174216BACKGROUND
  • Sadeghi R, Forghani MN, Memar B, Abdollahi A, Zakavi SR, Mashhadi MT, Raziee HR, Tavassoli A, Kakhki VR. Comparison of pre-operative lymphoscintigraphy with inter-operative gamma probe and dye technique regarding the number of detected sentinel lymph nodes. Hell J Nucl Med. 2009 Jan-Apr;12(1):30-2.

    PMID: 19330179BACKGROUND
  • Hubalewska-Dydejczyk A, Sowa-Staszczak A, Huszno B. Current application of sentinel lymph node lymphoscintigraphy to detect various cancer metastases. Hell J Nucl Med. 2006 Jan-Apr;9(1):5-9.

    PMID: 16617387BACKGROUND

MeSH Terms

Conditions

Breast Neoplasms

Interventions

LymphoscintigraphyTomography, Emission-Computed, Single-Photon

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Radionuclide ImagingDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, RadioisotopeTomography, Emission-ComputedImage Interpretation, Computer-AssistedImage EnhancementPhotographyTomography

Central Study Contacts

Raghda Farweiz, Ass lecturer

CONTACT

Nadia Mohany, lecturer

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assiut Medical School Ethical Review Board

Study Record Dates

First Submitted

March 4, 2018

First Posted

March 16, 2018

Study Start

July 1, 2018

Primary Completion

October 1, 2019

Study Completion

September 1, 2022

Last Updated

March 16, 2018

Record last verified: 2018-02